A Phase 1/2 interventional study of Glucagon response study in Obesity, Type2diabetes and NAFLD, sponsored by Adrian Vella. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Adrian Vella · Phase 1/2, Interventional, and Basic science
…and 15 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid catabolism and EGP interact with hepatic lipid metabolism in lean and obese subjects with and without T2DM (and with varying degrees of hepatic steatosis).
T2DM and prediabetes are characterized by abnormal post-prandial suppression of glucagon, which contributes to postprandial hyperglycemia by increasing EGP. Although these effects are magnified by decreased and delayed insulin secretion, they are also apparent when insulin secretion is intact. In rodents, altered glucagon signaling changes α-cell function and mass - an effect mediated by changes in circulating AA concentrations. Are the elevated concentrations of branched-chain AA and other AA metabolites in T2DM a cause or an effect of global α-cell dysfunction? Could altered glucagon signaling precipitate a vicious cycle resulting in T2DM?
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's enrollment of 21 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Adrian Vella is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 14, 2026. See what changed
Inclusion Criteria - Obese Subjects with Type 2 Diabetes:
Exclusion Criteria - Obese Subjects with Type 2 Diabetes:
Inclusion Criteria - Obese subjects without Type 2 Diabetes:
-Obese subjects without type 2 diabetes but are age, sex and weight-matched (BMI ≥ 28 Kg/M2) with subjects who have T2DM
Exclusion Criteria - Obese Subjects without Type 2 Diabetes:
Inclusion Criteria - Lean subjects without Diabetes:
-Subjects who do not have type 2 diabetes but are age and sex but are not weight-matched (BMI ≤ 25 Kg/M2) with subjects who have T2DM
Exclusion Criteria - Lean subjects without Diabetes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Drug: Glucagon response study
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Drug: Glucagon response study
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Drug: Glucagon response study
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Drug: Glucagon response study
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Drug: Glucagon response study
Please see information in group descriptions
Also known as: Glucagon
Rate of Amino Acid Catabolism in the Presence / Absence of Glucagon
Amino acid catabolism assessed by leucine reamination, a surrogate measure of leucine oxidation, during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes).
Time frame: 0 minutes, 120 minutes, 240 minutes
Effect of Diabetes on Amino-acid Catabolism
Tracer-dependent measurement of amino-acid clearance
Time frame: 240 minutes of study
Splanchnic Balance of Essential Amino Acids During Fasting and Glucagon Infusion
Splanchnic balance of essential amino acids calculated from the arteriovenous concentration difference across the liver multiplied by splanchnic blood flow. Measurements were obtained during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes) to evaluate the effect of obesity and hepatic steatosis on glucagon-mediated amino acid metabolism.
Time frame: 0 Minutes, 120 Minutes, 240 Minutes
Splanchnic Balance of Nonessential Amino Acids During Fasting and Glucagon Infusion
Splanchnic balance of nonessential amino acids calculated from the arteriovenous concentration difference across the liver multiplied by splanchnic blood flow. Measurements were obtained during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes) to evaluate the effect of obesity and hepatic steatosis on glucagon-mediated amino acid metabolism.
Time frame: 0 Minutes, 120 Minutes, 240 Minutes
| Milestone | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Subjects Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% |
|---|---|---|---|---|---|
| Started | 7 | 6 | 7 | 0 | 0 |
| Completed | 7 | 6 | 7 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Amino acid catabolism assessed by leucine reamination, a surrogate measure of leucine oxidation, during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes).
| mmol/min | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Subjects Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% |
|---|---|---|---|---|---|
| Fasting (0 Minutes) | 17 ± 2 | 26 ± 5 | 20 ± 6 | — | — |
| Intermediate Glucagon Infusion (120 Minutes) | 12 ± 1 | 19 ± 2 | 22 ± 7 | — | — |
| High Glucagon Infusion (240 Minutes) | 10 ± 1 | 16 ± 2 | 14 ± 4 | — | — |
Tracer-dependent measurement of amino-acid clearance
No measurements were reported for this outcome.
Splanchnic balance of essential amino acids calculated from the arteriovenous concentration difference across the liver multiplied by splanchnic blood flow. Measurements were obtained during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes) to evaluate the effect of obesity and hepatic steatosis on glucagon-mediated amino acid metabolism.
| nmol/min | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Subjects Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% |
|---|---|---|---|---|---|
| Valine 0 Minutes | 1.1 ± 5.3 | 2.0 ± 2.3 | 0.5 ± 3.0 | — | — |
| Valine 120 Minutes | 4.0 ± 2.3 | 6.4 ± 1.1 | 3.9 ± 2.1 | — | — |
| Valine 240 Minutes | 4.7 ± 0.9 | 3.6 ± 1.3 | 6.4 ± 1.7 | — | — |
| Isoleucine 0 Minutes | 0.1 ± 1.4 | 0.6 ± 0.4 | -0.3 ± 1.0 | — | — |
| Isoleucine 120 Minutes | 2.4 ± 0.6 | 3.5 ± 0.7 | 2.0 ± 0.5 | — | — |
| Isoleucine 240 Minutes | 2.2 ± 0.3 | 1.8 ± 0.3 | 2.6 ± 0.5 | — | — |
| Leucine 0 Minutes | 0.1 ± 3.4 | 1.6 ± 1.2 | 0.1 ± 2.1 | — | — |
| Leucine 120 Minutes | 3.8 ± 1.3 | 5.2 ± 1.1 | 3.1 ± 1.1 | — | — |
| Leucine 240 Minutes | 4.1 ± 0.5 | 2.4 ± 0.6 | 4.2 ± 1.1 | — | — |
| Phenylalanine 0 Minutes | 1.9 ± 1.2 | 3.4 ± 0.6 | 1.2 ± 1.1 | — | — |
| Phenylalanine 120 Minutes | 4.1 ± 0.8 | 6.3 ± 0.5 | 3.6 ± 1.0 | — | — |
| Phenylalanine 240 Minutes | 5.2 ± 0.4 | 5.8 ± 0.5 | 4.6 ± 1.3 | — | — |
| Tryptophan 0 Minutes | 0.7 ± 1.4 | 2.1 ± 0.4 | 0.5 ± 0.9 | — | — |
| Tryptophan 120 Minutes | 1.2 ± 0.7 | 2.6 ± 0.4 | 1.6 ± 0.7 | — | — |
| Tryptophan 240 Minutes | 2.0 ± 0.2 | 2.3 ± 0.8 | 2.1 ± 0.6 | — | — |
| Tyrosine 0 Minutes | 4.2 ± 1.3 | 7.9 ± 0.9 | 2.9 ± 1.8 | — | — |
| Tyrosine 120 Minutes | 3.7 ± 0.5 | 6.4 ± 0.3 | 2.8 ± 1.3 | — | — |
| Tyrosine 240 Minutes | 3.1 ± 0.3 | 4.0 ± 0.4 | 2.9 ± 1.2 | — | — |
| Methionine 0 Minutes | 1.7 ± 0.5 | 3.0 ± 0.4 | 0.8 ± 0.7 | — | — |
| Methionine 120 Minutes | 4.2 ± 0.5 | 6.3 ± 0.3 | 3.1 ± 0.9 | — | — |
| Methionine 240 Minutes | 4.8 ± 0.4 | 6.6 ± 0.6 | 3.9 ± 1.2 | — | — |
| Cysteine 0 Minutes | 0.3 ± 0.8 | -0.4 ± 0.8 | 0.0 ± 0.6 | — | — |
| Cysteine 120 Minutes | -0.1 ± 0.4 | 1.3 ± 0.3 | -0.4 ± 0.6 | — | — |
| Cysteine 240 Minutes | 0.5 ± 0.3 | -0.7 ± 1.4 | 0.9 ± 0.6 | — | — |
| Histidine 0 Minutes | 1.2 ± 4.7 | 2.8 ± 1.0 | 2.4 ± 3.4 | — | — |
| Histidine 120 Minutes | 7.1 ± 2.5 | 11.2 ± 2.3 | 8.1 ± 1.2 | — | — |
| Histidine 240 Minutes | 10.9 ± 1.2 | 11.7 ± 2.3 | 10.5 ± 1.6 | — | — |
| Lysine 0 Minutes | 5.9 ± 3.6 | 10.5 ± 3.2 | 3.4 ± 4.3 | — | — |
| Lysine 120 Minutes | 7.1 ± 1.9 | 12.1 ± 1.8 | 6.5 ± 2.6 | — | — |
| Lysine 240 Minutes | 8.8 ± 0.8 | 8.7 ± 1.7 | 9.6 ± 2.3 | — | — |
| Proline 0 Minutes | 0.6 ± 4.6 | 5.2 ± 1.8 | 1.5 ± 3.5 | — | — |
| Proline 120 Minutes | 6.9 ± 1.8 | 10.2 ± 1.2 | 6.4 ± 2.0 | — | — |
| Proline 240 Minutes | 9.4 ± 0.8 | 9.5 ± 0.8 | 8.8 ± 2.2 | — | — |
| Threonine 0 Minutes | 7.2 ± 2.6 | 11.6 ± 1.9 | 3.6 ± 3.1 | — | — |
| Threonine 120 Minutes | 9.4 ± 1.1 | 13.8 ± 1.0 | 6.7 ± 2.4 | — | — |
| Threonine 240 Minutes | 10.2 ± 0.7 | 11.8 ± 1.1 | 8.1 ± 2.5 | — | — |
Splanchnic balance of nonessential amino acids calculated from the arteriovenous concentration difference across the liver multiplied by splanchnic blood flow. Measurements were obtained during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes) to evaluate the effect of obesity and hepatic steatosis on glucagon-mediated amino acid metabolism.
| nmol/min | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% | Obese Adults Protein Density Fat Fraction (PDFF) > 5% |
|---|---|---|---|---|---|
| Glycine 0 Minutes | -2.1 ± 9.0 | 13.8 ± 4.5 | 5.7 ± 4.8 | — | — |
| Glycine 120 Minutes | -1.9 ± 5.1 | 18.0 ± 4.1 | 11.7 ± 2.1 | — | — |
| Glycine 240 Minutes | 6.9 ± 2.2 | 20.8 ± 4.2 | 15.9 ± 2.5 | — | — |
| Alanine 0 Minutes | 43.1 ± 5.5 | 82.9 ± 11.4 | 32.8 ± 20.9 | — | — |
| Alanine 120 Minutes | 50.5 ± 4.9 | 81.0 ± 6.5 | 37.7 ± 14.6 | — | — |
| Alanine 240 Minutes | 74.2 ± 8.9 | 99.5 ± 9.9 | 55.1 ± 20.6 | — | — |
| Asparagine 0 Minutes | 4.1 ± 1.7 | 6.3 ± 1.0 | 2.1 ± 1.5 | — | — |
| Asparagine 120 Minutes | 4.0 ± 0.6 | 5.3 ± 0.9 | 2.6 ± 1.1 | — | — |
| Asparagine 240 Minutes | 3.9 ± 0.3 | 3.5 ± 0.6 | 2.7 ± 0.9 | — | — |
| Arginine 0 Minutes | 5.9 ± 2.3 | 8.2 ± 1.7 | 1.8 ± 2.5 | — | — |
| Arginine 120 Minutes | 11.3 ± 1.7 | 11.9 ± 0.7 | 5.1 ± 1.7 | — | — |
| Arginine 240 Minutes | 12.3 ± 1.1 | 11.1 ± 1.0 | 6.8 ± 1.5 | — | — |
| Glutamine 0 Minutes | 17.0 ± 16.0 | 35.6 ± 5.8 | 10.5 ± 10.3 | — | — |
| Glutamine 120 Minutes | 16.4 ± 5.9 | 36.0 ± 4.6 | 19.1 ± 4.8 | — | — |
| Glutamine 240 Minutes | 25.3 ± 4.0 | 27.2 ± 3.0 | 23.0 ± 5.8 | — | — |
| Glutamic Acid 0 Minutes | -30.2 ± 4.3 | -59.1 ± 5.8 | -29.0 ± 11.1 | — | — |
| Glutamic Acid 120 Minutes | -25.7 ± 2.8 | -46.1 ± 3.3 | -21.0 ± 11.2 | — | — |
| Glutamic Acid 240 Minutes | -25.0 ± 3.3 | -45.5 ± 5.2 | -20.9 ± 10.7 | — | — |
| Aspartic Acid 0 Minutes | -0.5 ± 0.1 | -0.6 ± 0.2 | -0.5 ± 0.3 | — | — |
| Aspartic Acid 120 Minutes | 0.5 ± 0.2 | 0.3 ± 0.2 | 0.3 ± 0.1 | — | — |
| Aspartic Acid 240 Minutes | 0.5 ± 0.2 | 0.3 ± 0.1 | 0.3 ± 0.1 | — | — |
| Serine 0 Minutes | 8.0 ± 3.7 | 12.2 ± 2.0 | 3.6 ± 2.8 | — | — |
| Serine 120 Minutes | 14.8 ± 2.1 | 19.5 ± 1.1 | 8.9 ± 3.2 | — | — |
| Serine 240 Minutes | 16.3 ± 2.0 | 19.4 ± 3.4 | 10.7 ± 3.2 | — | — |
Collected over Adverse events were collected from the time of informed consent through study completion, approximately 4 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Adults | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Obese Adults Protein Density Fat Fraction (PDFF) < 5% | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Obese Adults Protein Density Fat Fraction (PDFF) > 5% | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | — | — | — |
| Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% | — | — | — |
| Event | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Adults Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% |
|---|---|---|---|---|---|
| Femoral Site Bruising/TendernessInjury, poisoning and procedural complications | 4/7 | 4/6 | 3/7 | — | — |
| Back PainMusculoskeletal and connective tissue disorders | 3/7 | 3/6 | 4/7 | — | — |
| IV Site Bruising/TendernessInjury, poisoning and procedural complications | 3/7 | 1/6 | 2/7 | — | — |
| NauseaGastrointestinal disorders | 3/7 | 1/6 | 1/7 | — | — |
| HypotensionVascular disorders | 1/7 | 2/6 | 2/7 | — | — |
| General AchingGeneral disorders | 0/7 | 0/6 | 2/7 | — | — |
| DiarrheaGastrointestinal disorders | 1/7 | 0/6 | 0/7 | — | — |
| GI Upset, Feeling WarmGastrointestinal disorders | 1/7 | 0/6 | 0/7 | — | — |
| HeadacheNervous system disorders | 1/7 | 0/6 | 1/7 | — | — |
| Leg DiscomfortGeneral disorders | 1/7 | 0/6 | 0/7 | — | — |
0 subjects with Type 2 Diabetes were enrolled due to a lack of interest in participation.
| Age, Continuous(years) | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Adults Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% | Total |
|---|---|---|---|---|---|---|
| Mean | 38 ± 4 | 52 ± 5 | 46 ± 5 | — | — | 44.7 ± 11.8 |
| Sex: Female, Male(Participants) | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Adults Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 3 | 7 | — | — | 17 |
| Male | 0 | 3 | 0 | — | — | 3 |
| Ethnicity (NIH/OMB)(Participants) | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Adults Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | — | — | 0 |
| Not Hispanic or Latino | 7 | 6 | 7 | — | — | 20 |
| Unknown or Not Reported | 0 | 0 | 0 | — | — | 0 |
| Race (NIH/OMB)(Participants) | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Adults Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | — | — | 0 |
| Asian | 0 | 0 | 0 | — | — | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | — | — | 0 |
| Black or African American | 0 | 0 | 1 | — | — | 1 |
| White | 7 | 6 | 6 | — | — | 19 |
| More than one race | 0 | 0 | 0 | — | — | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | — | — | 0 |
| Region of Enrollment(participants) | Healthy Adults | Obese Adults Protein Density Fat Fraction (PDFF) < 5% | Obese Adults Protein Density Fat Fraction (PDFF) > 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5% | Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5% | Total |
|---|---|---|---|---|---|---|
| United States | 7 | 6 | 7 | — | — | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — No plan
Ran from Oct 2022 to primary completion in Sep 2025, 35 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 39 non-industry phase 1/2 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 35 months is above that.
Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 14 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
…and 15 more changes, on the record history on ClinicalTrials.gov ↗
…and 15 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glucagon
Adrian Vella